se gb

Akinion Pharmaceuticals AB has presented the New Anticancer Agent AKN-028 at The American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, USA

Link to the abstract: AKN-028, a FLT-3 Kinase Inhibitor In Preclinical Development, Induces Significant Gene Regulation That Differs From PKC-412

pdf_small.gif Download poster

For more information, please contact:
Vendela Parrow, PhD (CSO of Akinion Pharmaceuticals)
Phone: +46 70 410 71 84
Vendela.parrow@akinion.com

TO THE EDITORS

About AKN-028, FLT-3 and cancer
AKN-028 is an orally administered small-molecule FLT-3 kinase inhibitor with a unique profile. Preclinical data has shown strong anti-tumor effect on primary tumor cells from AML patients. FLT-3 is a validated target for AML with several compounds in development stage. Globally more than 12 million people are diagnosed with cancer every year. Cancer causes the death of about 8 million people annually. AML is a disease with very high unmet medical need for new efficacious non-toxic treatments.


About Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB is a Swedish biotech company founded in 2009. The company focuses its activities on research and development related to FLT-3 kinase inhibitors and their application in treating leukemia and autoimmune diseases. The business strategy is to outlicense projects after proof-of-concept clinical trials. Akinion Pharmaceuticals AB is a Karolinska Development portfolio company. www.akinion.com

2010-12-02